Date: November 14, 2026

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai - 400051.

Sub: Outcome of Board Meeting held today i.e. Saturday, November 14, 2026 in terms of second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Aristo Bio-Tech and Lifescience Limited | **SYMBOL:** ARISTO | **ISIN:** INE082101010

Dear Sir/Ma'am,

In reference to the captioned subject, we hereby inform that the Board of Directors of the Company, in their Board Meeting held today, i.e. Saturday, November 14, 2026 at the registered office of the company situated at E-24, 25, 26, G.I.D.C. Manjusar, Ta. Savli, Vadodara -391775, Gujarat, India, which commenced at 06:00 P.M. and concluded at 07:00 P.M., have apart from other businesses:

1. Considered, approved and taken on record the Unaudited Standalone Financial Results for the half year ended on September 30, 2026 along with Auditor's limited review report as per Regulation 33 of the SEBI (LODR) Regulations, 2015;

2. Considered and approved all other business as per agenda circulated.

The said Financial Results were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, at their respective meetings held today.

Kindly take the same on your record and oblige us.

Thanking you,

Yours faithfully,
For**, Aristo Bio-Tech and Lifescience Limited**

Narendra Singh Inder Singh Barhat

Digitally signed by Narendra Singh Inder Singh Barhat
DN: c=IN, o=Personal, postalCode=390024, l=Vadodara, st=Gujarat, street=A 201 NAKSHATRA HEIGHTS VADODARA, Vadodara, Gujarat India 390024 OPPOSITE URMI SCHOOL, title=5563, 2.5.4.20=dda78c9b229697f2141154108d025dd15fd1e9edc63af7eabd92b2de06795a1a, serialNumber=a42fdad0047b4c14b645f9862458f47003372671dfe526cbe4991eb7c5b99fdfa, email=barhatns@yahoo.com, cn=Narendra Singh Inder Singh Barhat
Date: 2026.11.14 20:19:12 +05'30'

Narendra Singh Barhat
Chairman & Managing Director
DIN: 00310306

Place: Vadodara

Date: November 14, 2026

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai - 400051.

Sub: Submission of Unaudited Standalone Financial Result of the Company for the half year ended September 30, 2026 along with Limited Review Report.

Ref: Aristo Bio-Tech and Lifescience Limited |**SYMBOL:** ARISTO | **ISIN:** INE082101010

Dear Sir/Ma'am,

In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the followings:

1. Unaudited Standalone Financial Results for the half year ended on September 30, 2026;
2. Limited Review Report issued by the Statutory Auditor.

Kindly take the same on your record and oblige us.

Thanking You,

Yours faithfully,
For**, Aristo Bio-Tech and Lifescience Limited**
Narendra Singh Inder Singh Barhat

Digitally signed by Narendra Singh Inder Singh Barhat
DN: c=IN, o=Personal, postalCode=390024, l=Vadodara, st=Gujarat, street=A 201 NAKSHATRA HEIGHTS VADODARA, Vadodara, Gujarat India 390024 OPPOSITE URMI SCHOOL, title=5583, 2.5.4.20=dda7f8c9b2296979211411540bd025dd15fd1e9edc63af7eabd92fe2de0670f5a1a, serialNumber=a426bad0047b4c140e64598624588f4700033726?1d9e52dcbe4999eb7c5b90dfa, email=barhatns@yahoo.com, cn=Narendra Singh Inder Singh Barhat
Date: 2026.11.14 20:19:34 +05'30'

Narendra Singh Barhat
Chairman & Managing Director
DIN: 00310306

Place: Vadodara

PRAKASH CHANDRA JAIN & CO.
Chartered Accountants

74-76, Gayatri Chambers,
Near Railway Station,
Alkapuri, Vadodara - 390 005.
Phone (O) 0265 - 2331056, 2334365
Mobile : 98980 99357
Fax : 91-265 2331056
E-mail : dcbarjatya@gmail.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON HALF YEARLY UNAUDITED INTERIM FINANCIAL RESULTS OF ARISTO BIOTECH LIFE-SCIENCE LIMITED PURSUTANT TO THE REGULATION 33 OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIRMENTS) REGULATIONS, 2015 AS AMENDED

REVIEW REPORT TO
THE BOARD OF DIRECTORS OF
ARISTO BIOTECH LIFE-SCIENCE LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of ARISTO BIOTECH LIFE-SCIENCE LIMITED (the "Company"), for the half year ended September 30, 2026 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "interim Financial Reporting" (AS 25)the prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

PRAKASH CHANDRA JAIN & CO.
Chartered Accountants

74-76, Gayatri Chambers,
Near Railway Station,
Alkapuri, Vadodara - 390 005.
Phone (O) 0265 - 2331056, 2334365
Mobile : 98980 99357
Fax : 91-265 2331056
E-mail : dcbarjatya@gmail.com

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR PRAKASH CHANDRA JAIN & CO.
(Chartered Accountants)
Reg No. :002438C

Dinesh Chand Jain

Digitally signed by Dinesh Chand Jain
DN: c=IN, o=Personal, 2.5.4.20=2d9d0ac1dd06e318a2a92fd64b45b29d08b1770552b61d58c63bd8f59b793da0, postalCode=390012, l=Vadodara, st=Gujarat, serialNumber=1a79b41af02e2eb311553d3472353cec30d42eb551a9751 3d76c501723b9c3f, email=fdajain57@yahoofreeb.com, cn=Dinesh Chand Jain
Date: 2026.11.14 17:54:13 +05'30'

CA DINESH C JAIN
(Partner)
B.Com. FCA, FAFD
M.No.: 041235
UDIN: 26041235REWOVX5217

Date:14/11/2026

Place: Vadodara

ARISTO BIO-TECH AND LIFESCIENCE LIMITED
E-24/25/26, G.I.D.C, Manjusar, Tal Savli, Dist. Vadodara, Gujarat, India - 391775
CIN: L01100GJ2005PLC127397

Statement of Unaudited Financial Results for the Half Year ended on 30th September 2026

(Rs. In lakh)

Sr. No.	PARTICULARS	6 Months Ended			Year Ended on
		30-09-2026	31-03-2026	30-09-2025	31-03-2026
A	Date of start of reporting period	01-04-2026	01-10-2025	01-04-2025	01-04-2025
B	Date of end of reporting period	30-09-2026	31-03-2026	30-09-2025	31-03-2026
C	Whether results are audited of unaudited	Unaudited	Audited	Unaudited	Audited
(I)	REVENUE FROM OPERATIONS	19,824.17	10,726.40	25,645.31	36,371.71
(II)	OTHER INCOME	15.94	37.04	8.61	45.65
(III)	**TOTAL REVENUE (I+II)**	**19,840.11**	**10,763.44**	**25,653.93**	**36,417.37**
(IV)	**EXPENSES :**				
	COST OF MATERIAL CONSUMED	17,787.33	9,326.49	23,941.68	33,268.16
	STORES & SPARES CONSUMED	-	-	-	-
	PURCHASES OF STOCK-IN-TRADE	-	-	-	-
	CHANGES IN INVENTORIES OF FINISHED GOODS	229.49	-214.01	23.08	-190.92
	WORK IN PROGRESS AND STOCK-IN-TRADE	-	-	-	-
	EMPLOYEE BENEFITS EXPENSE	236.33	280.01	217.01	497.02
	FINANCE COST	175.57	290.83	97.76	388.59
	DEPRECIATION AND AMORTIZATION EXPENSE	157.33	145.81	146.66	292.47
	OTHER EXPENSES	594.22	518.99	673.30	1,192.29
	TOTAL EXPENSES	**19,180.28**	**10,348.12**	**25,099.48**	**35,447.61**
(V)	**PROFIT BEFORE EXCEPTIONAL AND EXTRAORDINARY ITEMS AND TAX(III-IV)**	**659.84**	**415.32**	**554.44**	**969.76**
(VI)	**EXCEPTIONAL ITEMS**				
	PRIOR PERIOD ITEMS (NET)				
	OTHER EXCEPTIONAL ITEMS				
(VII)	**PROFIT BEFORE EXTRAORDINARY ITEMS AND TAX (V-VI)**	**659.84**	**415.32**	**554.44**	**969.76**
(VIII)	EXTRAORDINARY ITEMS				
(IX)	**PROFIT BEFORE TAX (VII-VIII)**	**659.84**	**415.32**	**554.44**	**969.76**
(X)	**TAX EXPENSE :**				
	1) SHORT PROVISION OF TAXES IN EARLIER YEAR		5.16	-5.16	0.00
	2) CURRENT TAX	145.93	143.78	114.60	258.37
	3) DEFERRED TAX	23.72	-34.93	28.05	-6.88
		169.65	114.01	137.49	
(XI)	**PROFIT/(LOSS) FROM ORDINARY ACTIVITIES (IX-X)**	**490.19**	**301.31**	**416.96**	**718.26**
(XII)	PROFIT/(LOSS) FROM DISCONTINUING OPERATION (BEFORE TAX) (XII-XIII)				
(XIII)	TAX EXPENSE OF DISCONTINUING OPERATION				
(XIV)	**PROFIT/(LOSS) FROM DISCONTINUING OPERATION (AFTER TAX) (XII-XIII)**				
(XV)	**PROFIT (LOSS) FOR THE PERIOD BEFORE MINORITY INTEREST (XI-XIV)**	**490.19**	**301.31**	**416.96**	**718.26**
	SHARE OF PROFIT/LOSS OF ASSOCIATES				
	SHARE OF PROFIT/LOSS OF MINORITY INTEREST				
	NET PROFIT (LOSS) FOR THE PERIOD	**-**	**-**	**-**	**-**
	DETAILS OF EQUITY SHARE CAPITAL				
	PAID UP EQUITY SHARE CAPITAL	680.78	680.78	680.78	680.78
	FACE VALUE OF EQUITY SHARE (PER SHARE) (in Rupees)	10.00	10.00	10.00	10.00
	DETAILS OF DEBT CAPITAL			-	-
	PAID UP DEBT CAPITAL			-	-
	FACE VALUE OF DEBT SECURITIES			-	-
	RESERVES EXCLUDING REVALUATION RESEREVS AS PER BALANCE SHEET OF PREVIOUS YEAR	4,219.96	3,729.77	3,469.31	3,729.77
(XVI)	**EARNINGS PER EQUITY SHARE :**				
	1) BASIC	7.20	4.43	6.12	10.55
	2) DILUTED	7.20	4.43	6.12	10.55

FOR ARISTO BIO-TECH AND LIFESCIENCE LIMITED

Narendra Singh Inder Singh Barhat

Digitally signed by Narendra Singh Inder Singh Barhat
DN: c=IN, o=Personal, postalCode=390024, l=Vadodara, st=Gujarat, street=A 201 NANDHATRA HEIGHTS VADODARA, Vadodara, Gujarat, India 390024 OPPOSITE URMI SCHOOL, title=5063, 2.5.4.20=dda78c9b229690f7214154108d825dd159d1e9edc61af7ea9d92b2e0e0679f5a1a, serialNumber=a4264e0004 7b4c14bd45f98624588470033726716fe52dcbe4997ab7c5b99d9a, email=barhatms@yahoo.com, cn=Narendra Singh Inder Singh Barhat
Date: 2026.11.14 20:19:50 +05'30'

NARENDRA SINGH BARHAT
(CHAIRMAN & MANAGING DIRECTOR)
(DIN-00310306)
PLACE: VADODARA
DATE: 14/11/2026

Notes attached to Unaudited Financial Results for the Half Year Ended on 30th September 2026	
1	The statutory auditor has carried out limited review report as on september 30,2026.
2	The above results have been reviewed by the Audit Committee and Subsequently approved by the Board of Directors on 14th November, 2026
3	These Financial Results have been prepared in accordance with the Generally Accepted Accounting Principles in India ("Indian GAAP") and comply with the provisions of Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules thereto, and other applicable accounting principles generally accepted in India, as amended from time to time.
4	The figures have been regrouped/ rearranged wherever necessary to make them comparable with the current period figures
5	Company is engaged in providing Best Quality manufacturing, formulation, supply and packaging, job work services for various Pesticides: Insecticides, Herbicides, Fungicides, Plant Growth Regulators and a wide variety of other Agrochemicals in India as well as for Export.
6	The company has only single reportable business segment and hence, seprate information for segment wise disclosure is not applicable in accordance with the requirements of accounting standard (AS) 17.
7	IND AS is not currently applicable to the company hence the statement is prepared in accordance with the requirement of Accounting Standards (AS) specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014.
8	Earning per Equity Share (EPS) is calculated on the weighted average share capital
9	There is no investor complaints received/pending as on September 30, 2026.
10	Contigent liability included Bank Guarantee provided to customer, contracts to be executed by company and Outstanding tax demand in respect of Sales Tax not considered as debt.

FOR ARISTO BIO-TECH AND LIFESCIENCE LIMITED

Narendra Singh Inder Singh Barhat

Digitally signed by Narendra Singh Inder Singh Barhat
DN: c=IN, o=Personal, postalCode=390024, l=Vadodara, st=Gujarat, street=A 201 NAKSHATRA HEIGHTS VADODARA, Vadodara, Gujarat India 390024 OPPOSITE URMI SCHOOL, title=5563, 2.5.4.20=dda78c9b229697f2141154108d025dd15fd1e9ed6b3af7eabd92b2de9d679fa1a, serialNumber=a42fdad0047b4c14b645f9862458f4700337267 1dfa92dcbe4991eb7c5b99dfa, email=barhatns@yahoo.com, cn=Narendra Singh Inder Singh Barhat
Date: 2026.11.14 20:20:04 +05'30'

NARENDRA SINGH BARHAT
(CHAIRMAN & MANAGING DIRECTOR)
(DIN-00310306)
PLACE: VADODARA
DATE: 14/11/2026

ARISTO BIO-TECH AND LIFESCIENCE LIMITED

E-24/25/26, G.I.D.C, Manjusar, Tal Savli, Dist. Vadodara, Gujarat, India - 391775

CIN: L01100GJ2005PLC127397

Unaudited Statement of Assets and Liablities as on 30th September 2026

(Rs. In lakh)

Sr. No.	PARTICULARS	As on 30-09-2026 Unaudited	AS on 31-03-2026 Audited
(I)	**EQUITY AND LIABILITIES**		
1	**SHARE HOLDER'S FUNDS**		
	A) SHARE CAPITAL	680.78	680.78
	B) RESERVES AND SURPLUS	4,219.96	3,729.77
	C) MONEY RECEIVED AGAINST SHARE WARRENTS		
2	**SHARE APPLICATION MONEY PENDING ALLOTMENT**		
3	**NON-CURRENT LIABILITIES**		
	A) LONG TERM BORROWINGS	777.25	763.14
	B) DEFERRED TAX LIABILITIES (NET)	24.52	0.80
	C) OTHER LONG TERM LIABILITIES	-	
	D) LONG TERM PROVISION	-	
4	**CURRENT LIABILITIES**		
	A) SHORT TERM BORROWINGS	2,880.88	2,776.72
	B) TRADE PAYABLE	-	-
	Total Outstanding Dues Of Micro enterprises And Small Enterprise	564.34	594.92
	Total Outstanding Dues Of Creditors Other Than Micro enterprises And Small Enterprise	9,072.04	6,490.20
	C) OTHER CURRENT LIABILITIES	494.41	157.51
	D) SHORT-TERM PROVISIONS	181.24	327.75
	TOTAL	**18,895.44**	**15,521.59**
(II)	**ASSETS**		
1	**NON-CURRENT ASSTES**		
	A) FIXED ASSETS		
	(I) TANGIBLE ASSETS	2,343.43	2,363.72
	(II) INTANGIBLE ASSETS	0.05	0.06
	(III) CAPITAL WORK-IN-PROGRESS		
	(IV) INTANGIBLE ASSSETS UNDER DEVELOPMENT		
	B) NON -CURRENT INVESTMENTS	18.29	18.29
	C) DEFERRED TAX ASSETS (NET)	-	-
	D) LONG TERM LOANS AND ADVANCES	21.89	6.72
	E) OTHER NON-CURRENT ASSETS	85.01	117.08
2	**CURRENT ASSETS**		
	A) CURRENT INVESTMENTS	-	-
	B) INVENTORIES	3,420.37	6,321.01
	C) TRADE RECEIVABLES	11,383.99	5,472.69
	D) CASH AND CASH EQUIVALENTS	254.65	262.65
	E) SHORT TERM LOANS AND ADVANCES	1,342.59	918.23
	F) OTHER CURRENT ASSETS	25.16	41.13
	TOTAL	**18,895.44**	**15,521.59**
		0.00	-0.00
(III)	**CONTINGENT LIABILITIES**	18.22	18.22

FOR ARISTO BIO-TECH AND LIFESCIENCE LIMITED

Narendra Singh Inder Singh Barhat

Digitally signed by Narendra Singh Inder Singh Barhat
DN: c=IN, o=Personal, postalCode=390024, l=Vadodara, st=Gujarat, street=A 201 NAKSHATRA HEIGHTS VADODARA, Vadodara, Gujarat India 390024 OPPOSITE URMI SCHOOL, title=5563, 2.5.4.20=dda78c9b229697f2f41154108d025d815fd1e9edc 6baf7eabd920a2eb967f5e1a, serialNumber=a42dad804d7b4c14b64f5f8662458f47003372 671d8cf23ddce490feab7c0b99dfa, email=lbarhatin@yahoo.com, cn=Narendra Singh Inder Singh Barhat
Date: 2026.11.14 20:20:16 +05'30'

NARENDRA SINGH BARHAT
(CHAIRMAN & MANAGING DIRECTOR)
(DIN-00310306)
PLACE: VADODARA
DATE: 14/11/2026

ARISTO BIO-TECH AND LIFESCIENCE LIMITED
E-24/25/26, G.I.D.C, Manjusar, Tal Savli, Dist. Vadodara, Gujarat, India - 391775
CIN: L01100GJ2005PLC127397

Unaudited Cash Flow Statement for the half year ended 30th September, 2026

(Rs. In lakh)

Particular	As on 30th September, 2026		As on 31st March, 2026	
	Amount (In Rs.)	Total Amount (In Rs.)	Amount (In Rs.)	Total Amount (In Rs.)
Cash flow from operating Activity				
Net Profit Before taxation and extraordinary activities		659.84		969.76
Adjustment				
Depreciation	157.33		292.47	
Profit/Loss on Sale of Car	-		-	
Interest Income	-8.35		-15.06	
Expenses Reported under other activity head	175.57	324.55	388.59	666.00
Current assets(other than cash)				
Increase/(Decrease) in Inventory	2,900.63		-1,584.43	
Increase/(Decrease) in Trade Receiavbles	-5,911.31		145.76	
Increase/(Decrease) in other current assets	15.97		21.05	
Increase/(Decrease) in Short Term Loans and Advances	-424.35	-3,419.06	129.12	-1,288.50
Current liabilities				
Increase/(Decrease) in Short term borrowing	104.16		1,355.30	
Increase/(Decrease) in Other Current liabalities	336.90		54.15	
Increase/(Decrease) in Trade payable	2,551.27		-755.51	
Increase/(Decrease) In Shot Term Provision	-146.51	2,845.82	135.59	789.53
Cash Generated from operation		**411.15**		**1,136.78**
less: Cash generated from discontinue business	-		-	
less: Income tax paid	-145.93		-258.37	
Add/(Less) : DTA	-23.72		6.88	
Less: Short Provision in Last Year	-		-0.00	
Less: Dividend Payable		-169.65	-	-251.49
Net Cash flow from operating activites :		**241.51**		**885.29**
Cash flow from Investing Activities				
Increase Capital Work In Progress	-		-	
Purchase of Fixed Assets	-137.03		-260.96	
Sale of Fixed Assets	-		-	
Decrease/(Increse) in Non Current Asset	32.07		-35.16	
Increase in Long Term Loans & Advances	-15.17		2.35	
Increse in Non Current Investment	-		-18.29	
Purchase of Tangible Assets	-		-	
Interest Income	8.35		15.06	
Net Cash flow from Investing Activities :		**-111.78**		**-297.00**
Cash flow from Financing Activities				
Increase in share capital (IPO)	-		-	
Security Premium (IPO)	-		-	
IPO Expense	-		-	
Interest Expense	-149.30		-251.83	
Finance Cost	-14.45		-26.34	
Foreign Exchange Loss	-11.82		-110.42	
Increase/(Decrease) In Long Term Borrowings	14.12		-0.86	
Increase/(Decrease) In Deferred Tax Liablity	23.72		-6.88	
Increase/(Decrease) In Other Long Term Liability	-		-	
Dividend paid	-		-40.85	
Net Cash flow from Financing Activities :		**-137.73**		**-437.19**
Net Increase in Cash & cash Equivalent		**-8.00**		**151.10**
Cash & cash equivalent at beginning of period		**262.65**		**111.55**
Cash & cash equivalent at end of period		**254.65**		**262.65**

FOR ARISTO BIO-TECH AND LIFESCIENCE LIMITED

Narendra Singh Inder Singh Barhat

Digitally signed by Narendra Singh Inder Singh Barhat
Date: 2026.11.14 20:20:46 +05'30'

NARENDRA SINGH BARHAT
(CHAIRMAN & MANAGING DIRECTOR)
(DIN-00310306)
PLACE: VADODARA
DATE: 14/11/2026